Clinical trials: Major Depressive Disorder (MDD)
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
This is an open-label, monotherapy, extension study to evaluate the safety and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
- Trial name
- NCT07161700
- Testing
- SPT-300
- Where
- 42 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Seaport Therapeutics
Major Depressive Disorder (MDD)
Physical Activity-based Intervention in Depressed Patients: Clinical, Neurophysiological, Epigenetic and Metabolic Correlates
The goal of this clinical trial is to investigate the effect of a structured physical activity (PA) program on depressive symptomatology in adults with a diagnosis of major depression disorder (MDD).
- Trial name
- NCT06989944
- Testing
- Physical Activity (PA) program
- Where
- 4 sites in Italy
- Volunteers
- 110 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD).
- Trial name
- NORLIGHT (NCT07284667)
- Testing
- ACP-211
- Where
- 28 sites in United States
- Volunteers
- 153 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Major Depressive Disorder (MDD
Brief Psychoanalytic Therapy Versus Cognitive Behavioral Therapy for Major Depressive Disorder
The goal of this clinical trial is to learn whether brief psychoanalytic therapy and cognitive behavioral therapy (CBT) reduce depressive symptoms in adults aged 18 to 65 who have been diagnosed with major depressive disorder.
- Trial name
- BPT-CBT-D (NCT07857629)
- Testing
- Brief Psychoanalytic Therapy, Cognitive Behavioral Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Istanbul Nisantasi University
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression
The goal of this study is to collect feasibility data on combining structured exercise aimed to improve physical fitness, and intermittent TBS (iTBS) in treating individuals diagnosed with difficult-to-treat depression who are…
- Trial name
- NCT06773949
- Testing
- Theta burst stimulation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Major Depressive Disorder (MDD)
Precision Depression Adalimumab Trial
The goal of this clinical trial is to learn if the anti-inflammatory medication adalimumab improves depressive symptoms in adults with Major Depressive Disorder (MDD) who are already taking the anti-depressant medication Lexapro…
- Trial name
- PDAT (NCT07845604)
- Testing
- Adalimumab Biosimilars Injection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Daniel Moriarity
Major Depressive Disorder (MDD)
Personalized Accelerated iTBS Versus Sham for Major Depressive Disorder
This randomized, double-blind, sham-controlled, parallel-group clinical trial will evaluate the efficacy and safety of individualized functional connectivity-guided accelerated intermittent theta-burst stimulation (iTBS) in…
- Trial name
- iTBS-MDD (NCT07843875)
- Testing
- Personalized Functional-Connectivity-Targeted Accelerated iTBS
- Volunteers
- 90 people
- Sponsor
- Capital Medical University
Major Depressive Disorder (MDD)
Physical Therapy for Depression Quality of Life (Pilot Study Protocol)
Major Depressive Disorder (MDD) significantly impacts quality of life and health status. Standard treatments include medical, psychological, and pharmacological approaches, with physical therapy often playing a less central role.
- Trial name
- PTEduQoL-MDD (NCT06983405)
- Testing
- Physical Therapy Program for MDD
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Universidad San Jorge
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL.
- Conditions
- Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
- Trial name
- HORIZON (NCT07621237)
- Testing
- TNX-102 SL
- Where
- 27 sites in United States
- Volunteers
- 360 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Opioid Use Disorder, Major Depressive Disorder (MDD)
Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation
This study will compare transcranial magnetic stimulation (TMS) with sham TMS in people with opioid use disorder who are taking buprenorphine and have major depressive disorder with ongoing depressive symptoms.
- Trial name
- NCT07842601
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Kentucky
Major Depressive Disorder (MDD)
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder
- Trial name
- NCT06830044
- Testing
- Milsaperidone
- Where
- 53 sites in United States, Bulgaria and 2 more
- Volunteers
- 500 people
- Sponsor
- Vanda Pharmaceuticals
Major Depressive Disorder (MDD)
A Phase II Study to Evaluate NH102 for Depression
This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine .
- Trial name
- NH102-21 (NCT06842992)
- Testing
- NH102, Duloxetine Hydrochloride Enteric-coated Capsule
- Where
- 24 sites in China
- Volunteers
- 243 people
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Home-Based Randomized Trial of Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression
This study aims to evaluate the clinical efficacy and neurophysiological mechanisms of home-based spaced tDCS in TRD through a randomized, double-blind, sham-controlled trial conducted under remote supervision.
- Trial name
- NCT07834762
- Testing
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Diego
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Major Depressive Disorder (MDD
Amygdala-Targeted Transcranial Temporal Interference Stimulation for Major Depressive Disorder: A Randomized Sham-Controlled Trial of Clinical Efficacy and Neurobiological Mechanisms
This randomized, sham-controlled clinical trial aims to evaluate the efficacy and safety of amygdala-targeted transcranial temporal interference stimulation (tTIS) in adults with major depressive disorder (MDD) and to explore its…
- Trial name
- NCT07829575
- Testing
- Transcranial Temporal Interference Stimulation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University
Major Depressive Disorder (MDD)
Imaging- vs. Scalp-Targeted Accelerated TMS for Depression: The Number Needed to Scan Trial
Transcranial magnetic stimulation(TMS) is a non-invasive form of brain stimulation that is cleared by the United States Food and Drug Administration (FDA) for depression.
- Trial name
- NNS (NCT07043738)
- Testing
- Transcranial Magnetic Stimulation
- Volunteers
- 160 people
- Sponsor
- Brigham and Women's Hospital
Post Traumatic Stress Disorder PTSD, Major Depressive Disorder (MDD)
Accelerated iTBS for PTSD and Depression
The goal of this pilot clinical trial is to learn if a faster brain stimulation schedule is practical, safe, tolerable, and acceptable. This study looks at accelerated intermittent theta burst stimulation, or accelerated iTBS.
- Trial name
- NCT07682207
- Testing
- Accelerated intermittent theta burst stimulation
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Lawson Research Institute of St. Joseph's
Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who…
- Trial name
- NCT07781293
- Testing
- Lurasidone, Background Antidepressant Therapy
- Volunteers
- 364 people
- Sponsor
- Bukwang Pharmaceutical
Major Depressive Disorder (MDD)
Pattern Separation in Major Depressive Disorder
This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on…
- Trial name
- NCT07139834
- Testing
- SSRI (escitalopram or sertraline), Extended-Release Memantine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jeffrey Miller
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in…
- Trial name
- NCT07217223
- Testing
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego